Skip to content

Contact +44 (0) 20 7060 7474 email us

CNS

Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies

 

Publication Date November 2008
Publisher Datamonitor
Product Type Report
Pages 257
ISBN Number not applicable
Product Code DAT01624

Price

£5,225.00
approximately: $8,003 | €5,822

pdf

Buy Now

print £8,050 ($12,330 | €8,970)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergicbased treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and maintain market share is growing as the patent expiries of three major brands draws near.

Scope

  • Analysis of key marketed brands and latestage pipeline drugs.
  • Anxiety disordersspecific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.
  • Identification of future market events that are expected to affect anxiety disorders drug revenues.
  • Analysis of patient potential, unmet needs and clinical trial design in anxiety disorder.

Highlights

Atypical antipsychotics are expected to change the landscape of the future anxiety disorders market, with Seroquel XR set to benefit from firsttomarket status upon approval in generalized anxiety disorder. Seroquel XR will be positioned as a second/thirdline treatment for patients who have failed to respond to available antidepressants. In view of the high comorbidity between anxiety and depression, it remains in the interests of antidepressant manufacturers to maximize the patient potential of their products. However, with three key brands set to experience patent expiration over the forecast period (20082017), competition within the antidepressant drug classes will intensify. The presence of neurokinin (NK) receptor antagonists and corticotrophin releasing factor (CRF) antagonists in the anxiety disorders pipeline have generated much interest among interviewed key opinion leaders. Datamonitor regards NK receptor antagonists as holding the greatest promise in the treatment of anxiety disorders.

Reasons to Purchase

  • Understand the current anxiety disorder market dynamics and how they are expected to evolve out to 2017.
  • Benchmark key latestage pipeline anxiety disorder compounds against the current market leading brands.
  • Understand unmet needs in the anxiety disorders market based on key opinion leader comments.

Contents

  • About Datamonitor Healthcare
    • About The Central Nervous System Pharmaceutical Analysis Team
  • Chapter 1 Executive Summary
    • Scope Of The Analysis
    • Contributing Experts
    • Datamonitor Insight Into The Anxiety Disorders Market
    • Related Reports
    • Upcoming Reports
  • Chapter 2 Patient Potential
    • Definition Of Anxiety Disorders
    • Classification Of Anxiety Disorders
    • Icd10 Classification
    • DsmIv Classification
    • Etiology Of Anxiety Disorders
    • Generalized Anxiety Disorder
    • Panic Disorder
    • Social Anxiety Disorder
    • ObsessiveCompulsive Disorder
    • PostTraumatic Stress Disorder
    • Agoraphobia
    • Specific Phobias
    • Acute Stress Disorder
    • Epidemiology Of Anxiety Disorders
    • Anxiety Disorders Are The Most Prevalent Psychiatric Conditions
    • Generalized Anxiety Disorder
    • Panic Disorder
    • Social Anxiety Disorder
    • ObsessiveCompulsive Disorder
    • PostTraumatic Stress Disorder And Acute Stress Disorder
    • Agoraphobia
    • Specific Phobias
    • Other Anxiety Disorders
    • Key Patient Segments
    • Acute Versus Chronic Anxiety
    • Anxiety Disorders Are Twice As Prevalent Among Women
    • Greater Research Is Required To Elucidate Reasons For The Greater Prevalence Of Anxiety Disorders In Women
    • Anxiety Disorders Are Characterized By An Early Age Of Onset
    • CoMorbidity Is A Fundamental Feature Of Anxiety Disorders
    • Depression Is The Most Common CoMorbid Condition Of Anxiety
    • Clinical Unmet Needs In Anxiety Disorders
    • Improvement In Response And Remission Rates
    • Limiting Side Effects Is Essential
    • Improving Patient Compliance
    • Diagnostic Unmet Needs In Anxiety Disorders
    • Need To Increase Low Diagnosis Rates
    • Raising Awareness Of Anxiety Disorders Is Necessary
  • Chapter 3 Market Overview
    • Current Treatment Classes And Mechanisms
    • Most Treatment Guidelines Recommend Ssris As FirstLine Treatment For Anxiety Disorders
    • Pharmacological Treatments
    • NonPharmacological Treatment
    • Current Market Assessment
    • The Anxiety Disorders Market Was Worth $4.1 Billion In 2007
    • Despite Experiencing The Greatest Decline In Sales, The Us Remained The Largest Market In 2007
    • Antidepressants And Mood Stabilizers Achieve The Greatest Sales Revenue, While Tranquillizers Dominate Volume Sales
    • The Top Six Brands Constitute Only 44% Of The Total Market
    • Mixed Anxiety And Depressive Disorders Account For A Quarter Of Market Value In 2007
    • Future Market Assessment
    • The Anxiety Disorders Market Is Set To Experience Modest Growth Over The Forecast Period 20082017
  • Chapter 4 Brand Dynamics
    • Marketed Brands Overview
    • Lexapro (Escitalopram, Lundbeck/Forest)
    • Drug Overview
    • Forecasts To 2017
    • Swot Analysis
    • Clinical Trial Data
    • Generalized Anxiety Disorder
    • Panic Disorder
    • Social Anxiety Disorder
    • ObsessiveCompulsive Disorder
    • Lexapro Side Effects
    • Effexor/Effexor Xr (Venlafaxine, Wyeth)
    • Drug Overview
    • Forecasts To 2017
    • Swot Analysis
    • Clinical Trial Data
    • Generalized Anxiety Disorder (Gad)
    • Social Anxiety Disorder
    • Panic Disorder
    • Effexor Xr Side Effects
    • Cymbalta (Duloxetine, Eli Lilly)
    • Drug Overview
    • Forecasts To 2017
    • Swot Analysis
    • Clinical Trial Data
    • Generalized Anxiety Disorder (Gad)
    • Cymbalta Side Effects
    • Paxil/Paxil Cr (Paroxetine, Glaxosmithkline)
    • Paxil/Paxil Cr Drug Overview
    • Forecasts To 2017
    • Swot Analysis
    • Clinical Trial Data
    • Social Anxiety Disorder
    • Panic Disorder
    • Paxil Cr Side Effects
    • Xanax/Xanax Xr (Alprazolam, Pfizer)
    • Drug Overview
    • Forecasts To 2017
    • Swot Analysis
    • Clinical Trial Data
    • Panic Disorder
    • Side Effects Of Xanax Xr
    • Lyrica (Pregabalin, Pfizer)
    • Drug Overview
    • Forecasts To 2017
    • Swot Analysis
    • Clinical Trial Data
    • Generalized Anxiety Disorder (Gad)
    • Side Effects Of Lyrica
  • Chapter 5 Pipeline Overview R&D Dynamics And Approach
    • Pipeline Overview
    • Glaxosmithkline Has A Strong Presence In The LateStage Anxiety Disorders Pipeline
    • GammaAminobutyric Acid (Gaba) Modulators Represent The Most Prevalent Drug Class In EarlyStage Development
    • Classification Of Pipeline Products
    • Corticotrophin Releasing Factor Antagonists
    • Neurokinin Receptor Antagonists
    • Nmda Receptor Modulators
    • Other Drug Classes
    • Discontinued And Suspended Projects
    • Pexacerfont (Bms562086)
    • Amibegron (Sr58611a)
    • Clinical Trial Design In Anxiety Disorders
    • Key Considerations In Clinical Trial Design Of Anxiety Disorder Trials
    • Results From Studies Which Exclude Patients With CoMorbid Psychiatric Conditions Have Limited Relevance To The Naturalistic Population
    • Progress Is Being Made In Clarifying The Term &Quot;Remission&Quot;
    • Clinical Trial Design Guidance
    • Inclusion Criteria
    • Exclusion Criteria
    • Assessing Efficacy
    • Key Research Recommendations
    • Primary Clinical Trial Endpoints And Anxiety Rating Scales
    • Hamilton Anxiety Scale
    • Hospital Anxiety And Depression Scale
    • Liebowitz Social Anxiety Scale
    • Social Phobia And Anxiety Inventory (Spai)
    • Social Phobia Inventory (Spin)
    • ClinicianAdministered Ptsd Scale
    • Treatment Outcome Ptsd Scale
    • Davidson Trauma Scale
    • Short Ptsd Rating Interview
    • Brief Social Phobia Scale
    • Panic Disorder Severity Scale
    • Panic And Agoraphobia Scale
    • YaleBrown ObsessiveCompulsive Scale
    • Secondary Clinical Trial Endpoints In Anxiety Disorders
    • Patient Global Impression Of Improvement Scale
    • Clinical Global Impression Improvement Scale
    • Sheehan Disability Scale
  • Chapter 6 LateStage Drug Analysis And Forecasts
    • Key LateStage Pipeline Summary
    • Comparative Forecasts
    • Comparative Drug Assessment
    • Definition Of Current Comparator Therapy
    • Forest/Lundbeck's Lexapro Is Datamonitor's Comparator Therapy
    • Clinical Trial Data
    • SideEffect Profile
    • Forecasted LateStage Pipeline Drugs
    • Seroquel Xr (Quetiapine Fumarate Extended Release, Astrazeneca)
    • Drug Overview
    • Forecasts To 2017
    • Marketing Factors
    • Patient Potential
    • Satisfaction Of Unmet Needs
    • Clinical Trial Data
    • Luaa21004 (Lundbeck, Takeda)
    • Drug Overview
    • Forecasts To 2017
    • Marketing Factors
    • Patient Potential
    • Satisfaction Of Unmet Needs
    • Clinical Trial Data
    • Tik101 (Tikvah Therapeutics)
    • Drug Overview
    • Forecasts To 2017
    • Marketing Factors
    • Patient Potential
    • Clinical Trial Data
    • Pd332334 (Pfizer)
    • Drug Overview
    • Forecasts To 2017
    • Marketing Factors
    • Patient Potential
    • Satisfaction Of Unmet Needs
    • Clinical Trial Data
    • Unforecasted LateStage Drugs
    • Saredutant (Sr48968, SanofiAventis)
    • Drug Overview
    • Despite Well Documented Failures Of Nk Receptor Antagonists In Treating Major Depressive Disorder, This Drug Class Still Holds Potential In Anxiety Disorders
    • Completed Clinical Trials
    • Osemozotan (Mn305, Medicininova)
    • Tgwooaa (FabreKramer)
    • Tgwooaa's Mechanism Of Action Is Not Particularly Unique
    • Efficacy In Treating Sexual Dysfunction Will Serve As A Key Product Differentiator
    • FabreKramer Will Need To Find A Marketing Partner
    • Abio0801 (Btg1640, Abiogen)
    • Casopitant (679769, Glaxosmithkline)
    • Bci540 (Braincells)
    • Gw876008 (Neurocrine, Glaxosmithkline)
    • Gsk561679 (Neurocrine, Glaxosmithkline)
    • Ph94b (Pherin)
    • Npl2003 (Neuropharm)
    • Rufinamide (Syn111, Synosia)
    • Nepicastat (Syn117, Synosia Therapeutics)
    • Sep225441 (Sepracor)
    • Luaa24530 (Takeda, Lundbeck)
    • Spn805 (Supernus)
    • Az002 (Alprazolam, Alexza, Symphony Allegro)
  • Bibliography
    • Journal Papers, Books, And Conference Abstracts
    • Websites
    • Datamonitor Reports
  • Appendix A Market Assumptions
    • New Product Launches
    • Patent Expiries
    • Data Definitions, Limitations And Assumptions
    • Standard Units
    • Japanese Market Data
    • Derivation Of Sales Forecasts And Pricing Trends
    • IndicationSpecific Sales Methodology
    • AnxietySpecific Sales Calculations
    • Diagnosis Values For Key Brands
    • Report Methodology
  • Appendix B
    • Contributing Experts
    • About Datamonitor Healthcare
    • About The Disease Analysis Team
    • Disclaimer
  • List Of Tables
    • Table 1: Icd10 Classification Codes For Anxiety Disorders
    • Table 2: DsmIv Classification Codes For Anxiety Disorders
    • Table 3: Prevalence Of Anxiety Disorder Subtypes Across The Seven Major Markets, 2008
    • Table 4: Prevalence Rates Of Generalized Anxiety Disorder
    • Table 5: Prevalence Of Generalized Anxiety Disorder In The Seven Major Markets, 2008
    • Table 6: Prevalence Rates Of Panic Disorder In The Seven Major Markets, 2008
    • Table 7: Prevalence Of Panic Disorder In The Seven Major Markets, 2008
    • Table 8: Prevalence Rates Of Social Anxiety Disorder
    • Table 9: Prevalence Of Social Anxiety Disorder In The Seven Major Markets, 2008
    • Table 10: Prevalence Rates Of ObsessiveCompulsive Disorder
    • Table 11: Prevalence Of ObsessiveCompulsive Disorder In The Seven Major Markets, 2008
    • Table 12: Prevalence Rates Of PostTraumatic Stress Disorder
    • Table 13: Prevalence Of PostTraumatic Stress Disorder (Ptsd) In The Seven Major Markets, 2008
    • Table 14: Prevalence Rates Of Agoraphobia Across The Seven Major Markets
    • Table 15: Prevalence Of Agoraphobia In The Seven Major Markets, 2008
    • Table 16: Prevalence Rates Of Specific Phobias
    • Table 17: Prevalence Of Specific Phobias In The Seven Major Markets, 2008
    • Table 18: Prevalence Of A CoMorbid Psychiatric Condition With Anxiety Disorders Across The Seven Major Markets
    • Table 19: Sales Of The Top Six Drugs Indicated For Anxiety Disorders, Seven Major Markets, 200607
    • Table 20: Seven Major Market Sales Forecast For Key Branded Drugs Within The Anxiety Disorders Market ($M), 20072017
    • Table 21: Leading Branded Drug Sales Revenue ($M) For Anxiety Disorders In The Seven Major Markets, 2007 And 2017
    • Table 22: Lexapro: Key Facts, 2008
    • Table 23: Key Clinical Trials Of Lexapro In The Treatment Of Generalized Anxiety Disorder
    • Table 24: Key Clinical Trial Results Of Lexapro In The Treatment Of Panic Disorder
    • Table 25: Key Clinical Trial Results Of Lexapro In The Treatment Of Social Anxiety Disorder (Sad)
    • Table 26: Key Clinical Trials Of Lexapro In The Treatment Of ObsessiveCompulsive Disorder
    • Table 27: Effexor/Effexor Xr: Key Facts, 2008
    • Table 28: Key Clinical Trials Of Effexor Xr In The Treatment Of Generalized Anxiety Disorder
    • Table 29: Key Clinical Trials Of Effexor Xr In The Treatment Of Social Anxiety Disorder
    • Table 30: Key Clinical Trials Of Effexor Xr In The Treatment Of Panic Disorder
    • Table 31: Cymbalta: Key Facts, 2008
    • Table 32: Key Clinical Trials Of Cymbalta In The Treatment Of Generalized Anxiety Disorder
    • Table 33: Paxil/Paxil Cr: Key Facts, 2008
    • Table 34: Key Clinical Trial Results Of Paxil Cr In The Treatment Of Social Anxiety Disorder (Sad)
    • Table 35: Key Clinical Trial Results Of Paxil Cr In The Treatment Of Panic Disorder
    • Table 36: Xanax Franchise: Key Facts
    • Table 37: Key Clinical Trials Of Xanax Xr In The Treatment Of Panic Disorder
    • Table 38: Lyrica: Key Facts
    • Table 39: Key Clinical Trials Of Lyrica In The Treatment Of Generalized Anxiety Disorder (Gad)
    • Table 40: Key Pipeline Drugs In LateStage Development For Anxiety Disorders, 2008
    • Table 41: Drugs In EarlyStage Development For Anxiety Disorders, 2008
    • Table 42: Number Of Key Anxiolytics By Class And Phase Of Development, 2008
    • Table 43: Forecasted Late Stage Pipeline Drugs, 2008
    • Table 44: Lexapro: Key Clinical Trial Results
    • Table 45: Factors Impacting On The Revenues Of Seroquel Xr, 20082017
    • Table 46: Factors Impacting On The Revenues Of Luaa21004, 20082017
    • Table 47: Phase Iii Trials Of Luaa21004 In Generalized Anxiety Disorder, 2008
    • Table 48: Factors Impacting The Revenues Of Tik101, 20082017
    • Table 49: Factors Impacting On The Revenues Of Pd332334, 20082017
    • Table 50: Pfizer's Anxiety Disorders Portfolio, 2008
    • Table 51: Phase Iii Trials Of Pd332334 Generalized Anxiety Disorder, 2008
    • Table 52: Phase Iii Trials Of Saredutant In Generalized Anxiety Disorder
    • Table 53: Key Facts: Phase Ii Trial Of Casopitant In Social Anxiety Disorder
    • Table 54: Key Facts: Phase Ii Trial Of Bci540 In Depression And Anxiety
    • Table 55: Key Facts: Phase Ii Trial Of Nlp2003 In ObsessiveCompulsive Disorder
    • Table 56: Key Facts: Phase Ii Trial Of Rufinamide In Generalized Anxiety Disorder
    • Table 57: Key Facts: Phase Ii Trial Of Nepicastat In PostTraumatic Stress Disorder
    • Table 58: Key Facts: Second Phase Ii Trial Of Nepicastat In PostTraumatic Stress Disorder
    • Table 59: Key Facts: Phase Ii Trial Of Sep225441 In Generalized Anxiety Disorder
    • Table 60: Datamonitor's Launch Dates For Anxiety Disorder Products Across The Us, 5eu And Japan, 20082017
    • Table 61: Patent Expiries Of Key Branded Anxiolytics Across The Us, The 5eu And Japan
    • Table 62: Patent Expiries Of Key Branded Drugs Prescribed OffLabel For Anxiety Disorders Across The Us, The 5eu And Japan
    • Table 63: Anxiety Diagnosis Values (%) For Key Brands Sales ($) In The Us, 200507
    • Table 64: Datamonitor Drug Assessment Parameters
  • List Of Figures
    • Figure 1: Datamonitor Drug Competitive Positioning Analysis Of Pipeline Drugs In Development For Anxiety Disorders In The Seven Major Markets Over The Forecast Period, 20082017
    • Figure 2: Historical (20042007) And Forecast (20082017) AnxietySpecific Sales Revenue For Key Marketed And Pipeline Drugs Across The 7mm
    • Figure 3: Prevalence Of Anxiety Disorder Subtypes Across The Seven Major Markets, 2008
    • Figure 4: Patient Distribution: Acute Versus Chronic Anxiety
    • Figure 5: Key Unmet Needs In The Treatment Of Anxiety Disorders, 2008
    • Figure 6: Value ($) And Volume (Su) Sales Of Anxiety Disorder Therapies Across The Seven Major Markets, 200407
    • Figure 7: Key Events Affecting The Anxiety Disorders Market, 200408
    • Figure 8: Anxiety DisorderSpecific Sales By Country In The Seven Major Markets, 200607
    • Figure 9: Share Of Key Drug Classes Used To Treat Anxiety Disorders In The Seven Major Market, 2007
    • Figure 10: Seven Major Market Sales Revenue Of The Leading Branded Anxiety Disorder Drugs, 200407
    • Figure 11: Total NonDirect To Consumer Promotional Spend Of Key Brands, 20052007
    • Figure 12: Seven Major Market Anxiety Disorder Sales Revenue By Indication, 2007
    • Figure 13: Anxiety DisorderSpecific Sales Revenue Across The Us, Japan And 5eu, ($M), 20042017
    • Figure 14: Key Events Impacting The Anxiety Disorders Market, 20082017
    • Figure 15: Lexapro (Escitalopram) Clinical And Commercial Attractiveness, 2008
    • Figure 16: Key Marketed Drugs Approved For Specific Anxiety Disorders In The Us, 5eu And Japan, 2008
    • Figure 17: Lexapro: Proportion Of Branded Anxiety Disorder Sales Across The Seven Major Markets, 200407
    • Figure 18: Lexapro AnxietySpecific Sales Revenue ($M) Across The Seven Major Markets, 200407 Historical, 20082017 Forecasts
    • Figure 19: Lexapro (Escitalopram): Swot Analysis For The Anxiety Disorders Market, 2008
    • Figure 20: Effexor/Effexor Xr: Proportion Of Branded Anxiety Disorder Sales Across The Seven Major Markets, 200407
    • Figure 21: Effexor/Effexor Xr AnxietySpecific Sales Revenue ($M) Across The Seven Major Markets, 200407 Historical, 20082017 Forecasts
    • Figure 22: Effexor Xr(Venlafaxine Extended Release): Swot Analysis For The Anxiety Disorders Market, 2008
    • Figure 23: Cymbalta: Proportion Of Branded Anxiety Disorder Sales Across The Seven Major Markets, 200407
    • Figure 24: Cymbalta AnxietySpecific Sales Revenue ($M) Across The Seven Major Markets, 200407 Historical, 20082017 Forecasts
    • Figure 25: Cymbalta (Duloxtine): Swot Analysis For The Anxiety Disorders Market, 2008
    • Figure 26: Paxil/Paxil Cr: Proportion Of Branded Anxiety Disorder Sales Across The Seven Major Markets, 200407
    • Figure 27: Paxil Franchise AnxietySpecific Sales Revenue ($M) Across The Seven Major Markets, 200407 Historical, 20082017 Forecasts
    • Figure 28: Paxil Cr (Paroxetine Controlled Release): Swot Analysis For The Anxiety Disorders Market, 2008
    • Figure 29: Xanax/Xanax Xr: Proportion Of Branded Anxiety Disorder Sales Across The Seven Major Markets, 200407
    • Figure 30: Xanax Franchise AnxietySpecific Sales ($M) Across The Seven Major Markets, 200407 Historical, 200817 Forecasts
    • Figure 31: Xanax Xr (Alprazolam Extended Release): Swot Analysis For The Anxiety Disorders Market, 2008
    • Figure 32: Lyrica AnxietySpecific Sales ($M) Across The Seven Major Markets, 200407 Historical, 200817 Forecasts
    • Figure 33: Lyrica (Pregabalin): Swot Analysis For The Anxiety Disorders Market, 2008
    • Figure 34: Drugs In Development For Anxiety Disorders By Class And Development Stage, 2008
    • Figure 35: Comparative LateStage Pipeline Anxiety Disorder Drug Sales Revenue Forecast, 20082017
    • Figure 36: Datamonitor Drug Assessment Summary Of Pipeline Drugs In Development For Anxiety Disorders Across The Seven Major Markets, 20082017
    • Figure 37: AnxietySpecific Sales Forecast Of Seroquel Xr In The Seven Major Markets, 20082017
    • Figure 38: Datamonitor's Competitive Positioning Analysis Of Seroquel Xr In Anxiety Disorders Across The Seven Major Markets, 20082017
    • Figure 39: Anxiety Specific Sales ($M) In The Seven Major Markets Of Seroquel/Seroquel Xr And Key Drugs Approved For Anxiety Disorders, 200407
    • Figure 40: AnxietySpecific Sales Forecast Of Luaa21004 In The Seven Major Markets, 20072017
    • Figure 41: Datamonitor's Competitive Positioning Analysis Of Luaa21004 In Anxiety Disorders Across The Seven Major Markets, 20082017
    • Figure 42: AnxietySpecific Sales Forecast Of Tik101 In The Seven Major Markets, 20082017
    • Figure 43: Datamonitor's Competitive Positioning Analysis Of Tik101 In Anxiety Disorders Across The Seven Major Markets, 20082017
    • Figure 44: AnxietySpecific Sales Forecast Of Pd332334 In The Seven Major Markets, 20082017
    • Figure 45: Datamonitor's Competitive Positioning Analysis Of Pd332334 In Anxiety Disorders Across The Seven Major Markets, 20082017
    • Figure 46: Phase Ii Results: Pd332334 In Generalized Anxiety Disorder